APA (7th ed.) Citation

Taskin, M. I., Topcu, O., Yay, A., Erken, G., Balcioğlu, E., Adali, E., & Hismiogulları, A. A. (2015). Prevention of ovarian hyperstimulation syndrome in a rat model: Comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist. Gynecological Endocrinology, 31(12), 949. https://doi.org/10.3109/09513590.2015.1077218

Chicago Style (17th ed.) Citation

Taskin, Mine Islimye, Onur Topcu, Arzu Yay, Gulten Erken, Esra Balcioğlu, Ertan Adali, and Adnan Adil Hismiogulları. "Prevention of Ovarian Hyperstimulation Syndrome in a Rat Model: Comparison of the Efficacy of Tocilizumab with That of Ranibizumab, Cabergoline, and a Gonadotropin-releasing Hormone Antagonist." Gynecological Endocrinology 31, no. 12 (2015): 949. https://doi.org/10.3109/09513590.2015.1077218.

MLA (9th ed.) Citation

Taskin, Mine Islimye, et al. "Prevention of Ovarian Hyperstimulation Syndrome in a Rat Model: Comparison of the Efficacy of Tocilizumab with That of Ranibizumab, Cabergoline, and a Gonadotropin-releasing Hormone Antagonist." Gynecological Endocrinology, vol. 31, no. 12, 2015, p. 949, https://doi.org/10.3109/09513590.2015.1077218.